TP53 and cholangiocarcinoma: Using a p53-deficient transgenic mouse model, a study on cholangiocarcinoma (CC) determined that the Wnt pathway is highly activated in CCs, suggesting that targeting Wnt signaling pathways has potential as a therapeutic strategy for cancers that can be pharmacologically inhibited36,37.